Novartis files global marketing application for its leading high blood pressure drug Diovan®, to improve survival and reduce cardiovascular events in high-risk patients following a heart attack
Basel, 30 January 2004 - Novartis Pharma AG announced it has filed an application to various regulatory authorities for a new indication for Diovanâ (valsartan) to improve survival and reduce cardiovascular events in patients at high-risk after surviving a heart attack. The application has been submitted in the US and in Europe to the Reference Member State, Sweden, as part of the Mutual Recognition Procedure, to the United Kingdom and Switzerland. Further filings are planned to other health authorities including France, Australia, Asian and Latin American countries during the next few weeks. Already approved for the first-line treatment of high blood pressure in more than 80 countries and for heart failure in more than 40 countries, Diovan is the fastest-growing branded high blood pressure treatment and also the second largest selling antihypertensive in the world.
Please see full press release under the following link:
